Key result
Single oral and intravenous doses of propafenone significantly prolonged ECG intervals, with the metabolite 5-hydroxy-propafenone showing an additive effect on QRS duration in 7 of 8 subjects.
Why the study?
Does oral propafenone compared to intravenous propafenone have different pharmacodynamic effects on ECG intervals in healthy extensive metabolizers?
RCT (n=8)
Single-blind
randomized
Does oral propafenone compared to intravenous propafenone have different pharmacodynamic effects on ECG intervals in healthy extensive metabolizers?
The major metabolite 5-hydroxy-propafenone exerts pharmacologic activity on ECG intervals and may contribute to the antiarrhythmic effect of oral propafenone.
Answers are grounded in this paper and cite their sources.
Oral propafenone ECG effects include active metabolite contribution; extends pharmacodynamic data and supports metabolite-aware dosing in extensive metabolizers.
The effect of propafenone and its major metabolite 5-hydroxy-propafenone on ECG intervals was investigated in eight healthy extensive metabolizers after single oral (300 to 450 mg) and intravenous (35 to 50 mg) doses of propafenone in a single-blind randomized trial. Peak serum concentrations were 278 +/- 233 ng/ml (oral) and 295 +/- 131 ng/ml (intravenous). After oral administration peak 5-hydroxy-propafenone levels were 194 +/- 65 ng/ml, whereas after intravenous dosing no metabolite was detected, except in one subject. Serum concentrations were related to effects by linear regression including a hypothetical effect-site compartment in a pharmacokinetic-pharmacodynamic model. Significant prolongations of ECG intervals were found in both sequences. Comparison of the two concentration-effect data sets (intravenous, oral) revealed an additive effect of 5-hydroxy-propafenone in four of eight subjects for PQ interval and seven of eight subjects for QRS duration. We conclude that 5-hydroxy-propafenone exerts pharmacologic activity and could thus contribute to the antiarrhythmic effect of propafenone.
No takes yet. Share an insight, caveat, or question.
Haefeli et al. (1990) conducted an RCT in healthy extensive metabolizers (n=8). Propafenone vs. Intravenous vs oral administration was evaluated on ECG intervals (PQ interval and QRS duration). Single oral and intravenous doses of propafenone significantly prolonged ECG intervals, with the metabolite 5-hydroxy-propafenone showing an additive effect on QRS duration in 7 of 8 subjects.
Synapse has enriched 10 related papers. Consider them for comparative context: